Insulin lispro protamine suspension in the treatment of patients with type 1 and type 2 diabetes mellitus: A systematic review of published data

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 2, 2012, Pages 255-281

  Ceriello, Antonio ^a   Cremasco, Francesco ^b   Romoli, Ester ^b   Rossi, Andrea ^b   Gentilella, Raffaella ^b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b Eli Lilly Italia SpA   (Italy)

Author keywords

Basal insulin; Insulin lispro; Insulin lispro protamine suspension (ILPS); Premixed formulations

Indexed keywords

EXENDIN 4; GLIBENCLAMIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; INSULIN LISPRO PROTAMINE; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIG INSULIN; SULFONYLUREA; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; BEDTIME DOSAGE; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; WEIGHT CHANGE; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN LISPRO; SUSPENSIONS;

EID: 84855900999     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.650862     Document Type: Review

References (48)

1. DeFelippis MR, Bakaysa DL, Bell MA, et al. Preparation and characterization of a cocrystalline suspension of [LysB28, ProB29]-human insulin analogue. J Pharm Sci 1998;87:170-6
2. Garber AJ. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs 2006;66(1):31-49 (Pubitemid 43144962)
3. Buse JB, Wolffenbuttel BH, Herman WH, et al. Durability of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care 2009;32(6):1007-13
4. Arakaki RF, Blevins TC, Liljenquist DR, et al. Efficacy and safety of insulin lispro protamine suspension (ILPS) versus insulin glargine (G) added to oral Antihyperglycaemic medications and exenatide in patients with type 2 diabetes. EASD; 2010
5. Koivisto V, Cleall S, Pontiroli AE, Giugliano D. Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial. Diabetes Obes Metab 2011;13:1149-57
6. Janssen MM, Casteleijn S, Deville W, et al. Nighttime insulin kinetics and glycemic control in type 1 diabetes patients following administration of an intermediate-acting lispro preparation. Diabetes Care 1997;20(12):1870-3 (Pubitemid 27522898)
7. Hompesch M, Ocheltree SM, Wondmagegnehu ET, et al. Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. Curr Med Res Opin 2009;25(11):2679-87
8. Ocheltree SM, Hompesch M, Wondmagegnehu ET, et al. Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. Eur J Endocrinol 2010;163(2):217-23
9. Esposito K, Ciotola M, Maiorino MI, et al. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. Ann Intern Med 2008;149(8):531-9
10. Strojek K, Shi C, Carey MA, Jacober SJ. Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens: a randomized trial. Diabetes Obes Metab 2010;12(10):916-22
11. Chacra AR, Kipnes M, Ilag LL, et al. Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 diabetes. Diabetes Med 2010;27(5):563-9
12. Fogelfeld L, Dharmalingam M, Robling K, et al. A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes. Diabetes Med 2010;27:181-8
13. Citro G, Lorusso B, Rossi A, et al. Insulin lispro protamine suspension in intensive insulin treatment: an Italian observational study. Curr Med Res Opin 2009;25(9):2259-65
14. Heise T, Weyer C, Serwas A, et al. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care 1998;21(5):800-3 (Pubitemid 28487075)
15. Roach P, Woodworth J, Gudat U, et al. A 75% insulin lispro/25% NPL mixture provides a longer duration of insulin activity compared with insulin lispro alone in patients with Type 1 diabetes. Diabetes Med 2003;20(11):946-52 (Pubitemid 41701496)
16. Koivisto VA, Tuominen JA, Ebeling P. Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients. Diabetes Care 1999;22(3):459-62 (Pubitemid 29106905)
17. Malone JK, Woodworth JR, Arora V, et al. Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus. Clin Ther 2000;22(2):222-30 (Pubitemid 30152101)
18. Malone JK, Yang H, Woodworth JR, et al. Humalog Mix25 offers better mealtime glycemic control in patients with type 1 or type 2 diabetes. Diabetes Metab 2000;26(6):481-7 (Pubitemid 32101820)
19. Schwartz S, Zagar AJ, Althouse SK, et al. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus. Clin Ther 2006;28(10):1649-57 (Pubitemid 44838900)
20. Roach P, Yue L, Arora V. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group. Diabetes Care 1999;22(8):1258-61 (Pubitemid 29350233)
21. Roach P, Trautmann M, Arora V, et al. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group. Clin Ther 1999;21(3):523-34 (Pubitemid 29198040)
22. Roach P, Strack T, Arora V, Zhao Z. Improved glycaemic control with the use of self-prepared mixtures of insulin lispro and insulin lispro protamine suspension in patients with types 1 and 2 diabetes. Int J Clin Pract 2001;55(3):177-82 (Pubitemid 32390155)
23. Herz M, Profozic V, Arora V, et al. Effects of a fixed mixture of 25% insulin lispro and 75% NPL on plasma glucose during and after moderate physical exercise in patients with type 2 diabetes. Curr Med Res Opin 2002;18(4):188-93
24. Roach P, Arora V, Campaigne BN, et al. Humalog Mix50 before carbohydrate-rich meals in type 2 diabetes mellitus. Diabetes Obes Metab 2003;5(5):311-16 (Pubitemid 37138861)
25. Roach P, Bai S, Charbonnel B, et al. Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus. Clin Ther 2004;26(4):502-10 (Pubitemid 38586451)
26. Roach P, Koledova E, Metcalfe S, et al. Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled with glyburide. Clin Ther 2001;23(10):1732-44 (Pubitemid 33063596)
27. Malone JK, Beattie SD, Campaigne BN, et al. Therapy after single oral agent failure: adding a second oral agent or an insulin mixture? Diabetes Res Clin Pract 2003;62(3):187-95 (Pubitemid 37414985)
28. Jacober SJ, Scism-Bacon JL, Zagar AJ. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naive patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes Obes Metab 2006;8(4):448-55 (Pubitemid 44349237)
29. Malone JK, Kerr LF, Campaigne BN, et al. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004;26(12):2034-44 (Pubitemid 40353613)
30. Malone JK, Bai S, Campaigne BN, et al. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes. Diabet Med 2005;22(4):374-81 (Pubitemid 40516233)
31. Roach P, Malone JK. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes. Diabetes Med 2006;23(7):743-9 (Pubitemid 44366072)
32. Robbins DC, Beisswenger PJ, Ceriello A, et al. Mealtime 50/50 basal plus prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Clin Ther 2007;29(11):2349-64
33. Gao Y, Li G, Li Y, et al. Postprandial blood glucose response to a standard test meal in insulin-requiring patients with diabetes treated with insulin lispro mix 50 or human insulin mix 50. Int J Clin Pract 2008;62(9):1344-51
34. Rosenstock J, Ahmann AJ, Colon G, et al. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008;31(1):20-5
35. Beattie SD, Kerr LN, Jacober SJ, et al. Comparing within-patient glucose variability in analog vs human insulin self-prepared mixture regimens (Insulin Lispro + Insulin Lispro Protamine Suspension vs Regular Human Insulin + NPH). Diabetologia 2007;50(Suppl 1):S396-7
36. Beisswenger PJ, Brown WV, Ceriello A, et al. Meal-induced increases in C-reactive protein, interleukin-6 and tumour necrosis factor alpha are attenuated by prandial + basal insulin in patients with type 2 diabetes. Diabetes Med 2011;28:1088-95
37. Miser WF, Arakaki R, Jiang H, et al. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial. Clin Ther 2010;32(5):896-908
38. Ahmann A, Jiang H, Martin S. Hypoglycemia rates with titration of prandial premixed (ILPS/Lispro) or basal bolus (Glargine/Lispro) insulin therapy in patients with type 2 diabetes (T2D). ADA 2008a, Abstract Number: 490-P. Available from: http://professional. diabetes.org/Abstracts-Display.aspx? TYP=1&CID=69799
39. Ahmann A, Jiang H, Martin S. A comparison of prandial premixed (ILPS/Lispro) vs. basal bolus (Glargine/Lispro) insulin therapy in obese patients with type 2 diabetes (T2D). ADA 2008b, Abstract Number: 2042-PO. Available from: http://professional.diabetes.org/Abstracts-Display.aspx? TYP=1&CID=70800
40. Martin S, Scism-Bacon J, Jiang H. A specific patient population achieves glycemic control with prandial premixed (Lispro/ILPS) insulin therapy with lower insulin dose and less weight gain than basal bolus therapy. Diabetologia 2008;51(Suppl 1):S393
41. Colon G, Jiang H, Martin S. Efficacy and safety of prandial premixed (ILPS/Lispro) vs. basal bolus (Glargine/Lispro) insulin therapy in Hispanic and African American patients with type 2 diabetes (T2D). ADA 2008, Abstract Number: 480-P. Available from: http://professional.diabetes.org/Abstracts-Display.aspx? TYP=1&CID=69788
42. Jiang H, Milicevic Z, Scism-Bacon J, Martin S. Effect of switching from insulin lispro Mix 50 to lispro Mix 25 at the evening meal during prandial premixed (Lispro/ILPS) therapy (PPT) in type 2 diabetes (T2D) patients. Diabetologia 2008;51(Suppl 1):S403
43. Hirsch IB, Yuan H, Campaigne BN, Tan MH. Impact of prandial plus basal vs basal insulin on glycemic variability in type 2 diabetic patients. Endocr Pract 2009;15(4):343-8
44. Roach P, Woodworth JR. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures. Clin Pharmacokinet 2002;41(13):1043-57 (Pubitemid 35246781)
45. Garber AJ, Ligthelm R, Christiansen JS, Liebl A. Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes Obes Metab 2007;9(5):630-9 (Pubitemid 47261844)
46. Bonafede MM, Kalsekar A, Pawaskar M, et al. Insulin use and persistence in patients with type 2 diabetes adding mealtime insulin to a basal regimen: a retrospective database analysis. BMC Endocr Disord 2011;11:3
47. Cavalot F, Petrelli A, Traversa M, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006;91(3):813-19 (Pubitemid 43357744)
48. Monnier L, Colette C, Owens DR. Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J Diabetes Sci Technol 2008;2(6):1094-100